Condition: Myeloproliferative Neoplasm · MPN · Essential Thrombocythemia · Sponsor: University of California, Irvine
This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).
This description comes directly from the study's public registry record.
Angela Fleischman, MD, PhD · (714) 456-8000 · agf@hs.uci.edu
University of California Irvine Medical Center
Always discuss trial participation with your own doctor first.
| University of California, Irvine | Irvine, California, United States | Recruiting |
| Chao Family Comprehensive Cancer Center, University of California, Irvine | Orange, California, United States | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05123365